《新股表現》達勢股份(01405.HK)平開報46元
達勢股份(01405.HK)暗盤收45.35元,低上市價1.4%;該股首掛開報46元,持平於上市價46元,市前成交52萬股。
達勢股份是達美樂比薩在內地及港澳地區的獨家總特許經營商。達勢於內地17個城市直營604家門店。達勢因應市況去年12月於掛牌前宣布延遲上市,今次捲土重來上市合共發售股份增至1,279.9萬股,其中10%公開發售獲不足額認購,未獲認購股份已重新分配至國際配售,令其佔比增至約95.5%,股份以招股範圍(46-55元)下限定價,料集資淨額約4.6億元,其中90%用作未來兩年擴張門店網絡。上市獨家保薦人為美銀證券。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.